Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2253109 | 0.97 | MEN1 (0.35) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL10236409 | 0.89 | MEN1 (0.32) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL13547345 | 0.89 | MEN1 (0.32) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL22142244 | 0.89 | MEN1 (0.32) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL13547239 | 0.87 | ALDH1A1 (0.36) | LMNAMEN1CYP2D6HRH1SCN1A | |
| Acetic Acid SCHEMBL31364149 | 0.85 | GABRA5 (0.44) | LMNAMEN1CYP2D6HRH1SCN1A | |
| Formic Acid SCHEMBL28915413 | 0.85 | LIPA (0.35) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL25134491 | 0.84 | GNAI3 (0.32) | EPHX1 | |
| Formic Acid SCHEMBL28915063 | 0.83 | LIPA (0.34) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL841864 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1494 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353835-A1 | N-TETRAZOLYL ARYL UREA-BASED DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | HANGZHOU YIRUI PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2025-11-20 | — | — | US | claimed |
| EP-4538261-A1 | N-TETRAZOLYL ARYL UREA DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | Hangzhou Yirui Pharmaceutical Technology Co., Ltd. (CN) | 2025-04-16 | — | — | EP | claimed |
| CN-112898170-B | Preparation method of acid diffusion inhibitor and photoresist composition | 宁波南大光电材料有限公司 | 2022-10-04 | — | — | CN | claimed |
| US-11034650-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | INTERVET INC. (US) | 2021-06-15 | — | — | US | claimed |
| CN-112898170-A | Preparation method of acid diffusion inhibitor and photoresist composition | 宁波南大光电材料有限公司 | 2021-06-04 | — | — | CN | claimed |
| EP-0494005-B1 | Multicomponent agent or kit for the preparation of the sulphoconjugated forms of pyridino-, pyrimidino- or triazino-N-oxyde compounds and method of application thereof | OREAL (FR) | 1997-02-05 | — | — | EP | claimed |
| US-5360804-A | STABILITY | L'OREAL (FR) | 1994-11-01 | — | — | US | claimed |
| EP-0494005-A1 | Multicomponent agent or kit for the preparation of the sulphoconjugated forms of pyridino-, pyrimidino- or triazino-N-oxyde compounds and method of application thereof | L'OREAL (FR) | 1992-07-08 | — | — | EP | claimed |
| EP-0369335-A2 | 2-Aminodecaline derivatives and their use | BASF Aktiengesellschaft (DE) | 1990-05-23 | — | — | EP | claimed |
| EP-0249999-A2 | Triazolyl ethyl ethers and fungicides containing them | BASF Aktiengesellschaft (DE) | 1987-12-23 | — | — | EP | claimed |
| US-20260092138-A1 | BLOCKED POLYISOCYANATE COMPOSITION, CURABLE RESIN COMPOSITION COMPRISING THE COMPOSITION, AND CURED PRODUCT | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20250353835-A1 | N-TETRAZOLYL ARYL UREA-BASED DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | HANGZHOU YIRUI PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2025-11-20 | — | — | US | disclosed |
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4570317-A2 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | Intervet International B.V. (NL) | 2025-06-18 | — | — | EP | disclosed |
| US-4005077-A | DERIVATIVES OF RIFAMYCIN S OR SV | CIBA-GEIGY CORPORATION (US) | 1977-01-25 | — | — | US | disclosed |
| US-3995035-A | 6-Amino-2-lower-alkyl-4-nitropyridine N-oxide compositions and coccidiostat process | THE UPJOHN COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
| US-3957989-A | ADMINISTERING | RICHARDSON-MERRELL INC. (US) | 1976-05-18 | — | — | US | disclosed |
| US-3937842-A | METHOD OF TREATING CONDITIONS OF DELAYED HYPERSENSITIVITY USING BIS-BASIC SUBSTITUTED ACENAPHTHENE DERIVATIVES | RICHARDSON-MERRELL INC. (US) | 1976-02-10 | — | — | US | disclosed |
| US-3937833-A | DELAYED HYPERSENSITIVITY | RICHARDSON-MERRELL INC. (US) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034650-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | HEXD, SORD, SDHA | LMNA 851/4885MEN1 3451/4885CYP2D6 1418/4885 |
| US-20260092138-A1 | BLOCKED POLYISOCYANATE COMPOSITION, CURABLE RESIN COMPOSITION COMPRISING THE COMPOSITION, AND CURED PRODUCT | RER1, RPP30, REV1 | LMNA 2244/4885MEN1 3615/4885CYP2D6 2833/4885 |
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | LMNA 3809/4885MEN1 601/4885CYP2D6 4469/4885 |
| US-20250353835-A1 | N-TETRAZOLYL ARYL UREA-BASED DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | BDKRB1, BDKRB2, UTS2R | LMNA 2057/4885MEN1 1907/4885CYP2D6 1719/4885 |
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | GPR39, GPR139, GPR119 | LMNA 4511/4885MEN1 3377/4885CYP2D6 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.